<DOC>
	<DOCNO>NCT01270087</DOCNO>
	<brief_summary>The purpose study determine whether anti-inflammatory treatment adalimumab ( Humira ) reduce endothelial activation blood vessel patient active rheumatoid arthritis . Markers endothelial activation assess muscle tissue treatment 3 month , related biomarkers clinical outcome .</brief_summary>
	<brief_title>The Effect Adalimumab ( Humira ) Vascular Abnormalities Rheumatoid Arthritis . A Pilot Study .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Clinical diagnosis rheumatoid arthritis Fulfillment American College Rheumatology 1987 criterion rheumatoid arthritis Active disease despite treatment least one disease modify antirheumatic drug Treatment adalimumab indicate accord patient 's rheumatologist At least six swollen joint 28joint index CRP &gt; 8 mg / L within last three month Treatment antiTNF drug last three month Treatment intravenous corticosteroid within fourteen day Ongoing treatment oral highdose corticosteroid ( equivalent â‰¥ 20 mg prednisolon daily ) complete treatment le fifteen day inclusion Severe bleed disorder Extensive refractory leg ulcer Severe peripheral vascular disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
	<keyword>Rheumatoid arthritis , cardiovascular disease , adalimumab</keyword>
</DOC>